Much of the potential of precision medicine rests on drug delivery strategies. What is achievable with current drug carriers and where do we need to focus in our current pipeline? How can precision medicine benefit from nanomedicine? And if the future of precision medicine lies in altering nucleic acid, then where do we need to focus our research to make it a reality?

Heinrich-Haas resized.jpg
Heinrich Haas
Vice President RNA Formulation & Drug Delivery at BioNTech RNA Pharmaceuticals, Mainz, Germany

Engineering Nanomedicines for RNA Delivery in Tumor Immunotherapy
In this session, we give insight into the targeting coherences within intravenously injectable messenger RNA (mRNA) lipoplex nanoparticle formulations, applicable for tumor therapy and further therapeutic approaches. Accurate control of the nanoparticulate organization at the molecular scale enabled design of vehicles for efficient targeting of different organs with high selectivity. Methods for semi-automated manufacturing of personalized vaccines for tumor immunotherapy as ready-to-use products could be developed. Several clinical trials have been initiated or are underway

James Taylor.jpg
James Taylor
Co-founder, CEO at Precision NanoSystems, Inc., Vancouver, Canada

Rapid Development and Scalable Manufacture of Precision Nanomedicines  
The past decade has seen the rapid development of new powerful therapeutic modalities, including advances in small molecule, protein, and nucleic acid based drugs with the potential to treat disease at the molecular level.  Nanoparticle delivery is a key enabling technology to transfer these new therapeutic advances into clinical realities. This talk will present the use of continuos-flow microfluidic manufacturing for the rapid and scalable development of nanomedicines.   
Twan Lammers.jpg
Twan Lammers 
Head of department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen 

Towards Precision Nanomedicine
Hundreds of tumor-targeted drug delivery systems are developed every day. However, hardly any of these so-called nanomedicine formulations have
been approved for clinical use. This is likely largely due to the lack of 
(imaging) biomarkers to pre-select patients for such targeted nanomedicine treatments. In this lecture, Twan Lammers will discuss strategies to improve the performance and clinical translation of tumor-targeted nanomedicine, and explain how imaging can be used to individualise and improve nanomedicine treatments. 

To download the full programme, click here.